Compare KOPN & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOPN | ACOG |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | United States |
| Employees | 145 | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.9M | 193.6M |
| IPO Year | 2025 | 2024 |
| Metric | KOPN | ACOG |
|---|---|---|
| Price | $4.64 | $8.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $8.43 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.7M | 89.3K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.03 | 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | $1,530,311.00 | ★ $10,220,275.00 |
| Revenue This Year | $54.14 | $152.34 |
| Revenue Next Year | $31.17 | $91.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 46.53 | N/A |
| 52 Week Low | $1.81 | $4.50 |
| 52 Week High | $6.61 | $10.14 |
| Indicator | KOPN | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 56.15 |
| Support Level | $4.14 | $5.49 |
| Resistance Level | $5.53 | $9.95 |
| Average True Range (ATR) | 0.21 | 0.47 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 46.32 | 93.62 |
Kopin Corp is a developer and provider of inventive display, and application-specific optical solutions sold as critical components and subassemblies for defense, enterprise, professional and consumer products. Its portfolio includes micro displays, display modules, eyepiece assemblies, image projection modules, and vehicle mounted and head-mounted display systems that incorporate ultra-small high-resolution Active Matrix Liquid Crystal displays (AMLCD), Ferroelectric Liquid Crystal on Silicon (FLCoS) displays, MicroLED displays (uLED) and Organic Light Emitting Diode (OLED) displays, a variety of optics, and low-power ASICs. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.